Tambotatug pelitecan not checked

MediLink Therapeutics (Suzhou) Co., Ltd. · YL201

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
12 active
12 in total · 2 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
How it’s given
“YL201 will be administered intravenously on Day 1 of each 3-week cycle at RP3D dose level.”In the company’s words, NCT06629597 on ClinicalTrials.gov
Tested for
Small Cell Lung Cancer (2 trials), Advanced Solid Tumor (2 trials), Advanced Solid Tumors (2 trials), Nasopharyngeal Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), SCLC, Extensive Stage and 4 more
Main trialPhase 3
“This study was designed to compare the efficacy and safety of YL201 with Investigator's choice of chemotherapy in subjects with recurrent or metastatic nasopharyngeal carcinoma who have failed prior PD-(L)1 inhibitor and at least two lines of chemotherapy.”In the company’s words, NCT06629597 on ClinicalTrials.gov
Other names
YL201 · Tam-Peli

Other drugs for Small Cell Lung Cancer

All 118 drugs for Small Cell Lung Cancer

Coming up11

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials12

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 1 Dec 2027 A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)
Phase 3Active, not recruiting 1 Dec 2027 A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)
Phase 3Recruiting 30 Apr 2028 A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Phase 3Not yet recruiting Jan 2029 A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy
Phase 3Recruiting Jun 2029 A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
Phase 2Recruiting Feb 2027 A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
Phase 1/2Active, not recruiting Oct 2026 A Study YL201 in Patients With Selected Advanced Solid Tumors
Phase 1/2Recruiting Jan 2027 A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Phase 1/2Recruiting 6 Apr 2027 A Study of YL201 in Patients With Advanced Solid Tumors
Phase 1/2Recruiting Feb 2028 A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Phase 1/2Recruiting Nov 2028 A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Phase 1Active, not recruiting 29 Apr 2027 A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Tambotatug pelitecan

Following is part of Solo: you see every change to Tambotatug pelitecan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in